ClinicalTrials.gg
CompletedNCT05882357Updated Oct 15, 2026Results posted

Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age

A Phase 3 interventional study of ELX/TEZ/IVA and IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 19 sites in 7 countries. Open to participants aged 12 Months to 24 Months. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment

Updated Oct 15, 2026Results postedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
67
Allocation
Non-randomized
Ages
12 Months to 24 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing elexacaftor in Cystic Fibrosis — 2 open to participants now, 5 under way, 2 of them phase 3. elexacaftor · Cystic Fibrosis.

Enrollment
20th of 23
67 · median 120
Started
2023
the only one that year
Phase 3
19 of 23
none open now
Registered
20th of 23
by date
Lead sponsor
20 of 23
Vertex Pharmaceuticals Incorporated

Among the 23 studies testing elexacaftor in Cystic Fibrosis, this one is the 20th largest by enrollment, is the only one that started in 2023, is one of 19 in phase 3, and was the 20th registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

2 of the 23 studies testing elexacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About elexacaftor

elexacaftor: first FDA approval 2019 (TRIKAFTA (COPACKAGED)), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 12 Months to 24 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing elexacaftor in Cystic Fibrosis, or all of them as a file.
02

Study summary

The study evaluates the pharmacokinetics (PK), safety, tolerability, pharmacodynamics (PD), and efficacy of ELX/TEZ/IVA in CF participants 2 to less than (\<) 24 months of age.

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
12 Months to 24 Months
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

Participants who have at least 1 F508del mutation in the CF transmembrane conductance regulator (CFTR) gene or another ELX/TEZ/IVA-responsive CFTR mutation

Key Exclusion Criteria:

History of any illness or any clinical condition that, in the opinion of the investigator, might either confound the results of the study or pose an additional risk in administering study drug(s) to the participant

Other protocol defined Inclusion/Exclusion criteria may apply.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
67 participants (actual)

Study arms

  • Experimental
    Part A: ELX/TEZ/IVA

    Participants received ELX 40 milligram (mg)/ TEZ 20 mg/IVA 30 mg fixed-dose combination (FDC) granules once every morning (qAM) and 25 mg IVA once every evening (qPM) for 15 Days.

    Drug: ELX/TEZ/IVA · Drug: IVA

  • Experimental
    Part B: ELX/TEZ/IVA

    Participants received one of three dosing regimens based on their body weight at Day 1 . Dosage 1: ELX 80 mg qAM/TEZ 40 mg qAM /IVA 60 mg qAM FDC granules and 59.5 IVA mg qPM; Dosage 2: ELX 60 mg qAM /TEZ 30 mg qAM /IVA 45 mg qAM FDC granules and 50 mg IVA qPM; Dosage 3: ELX 40 mg qAM / TEZ 20 mg qAM /IVA 30 mg qAM FDC granules and 25mg IVA qPM. Part B included some participants from Part A and newly enrolled participants.

    Drug: ELX/TEZ/IVA · Drug: IVA

Interventions

  • DrugELX/TEZ/IVA

    Drug pages: Elexacaftor · Tezacaftor · Ivacaftor

    Fixed-dose combination granules for oral administration.

    Also known as: VX-445/VX-661/VX-770, elexacaftor/tezacaftor/ivacaftor

  • DrugIVA

    Granules for oral administration

    Also known as: VX-770, ivacaftor

06

What researchers measure

Primary outcomes

  1. Part A: Observed Pre-dose Concentration (Ctrough) of ELX, TEZ, IVA, and Their Relevant Metabolites (M23-ELX, M1-TEX, M1-IVA)

    Time frame: At Day 15

  2. Part A: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: Day 1 up to Day 43

  3. Part B : Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: Day 1 up to Week 28

Secondary outcomes

  1. Part B: Observed Pre-dose Concentration (Ctrough) of ELX, TEZ, IVA, and Their Relevant Metabolites (M23-ELX, M1-TEZ, M1-IVA)

    Time frame: Day 15, Week 4, 12 and 16

  2. Part B: Absolute Change in Sweat Chloride (SwCl) From Baseline Through Week 24

    Time frame: From Baseline through Week 24

07

Results

Posted Oct 15, 2026

Participant flow

The study comprised of two parts: Part A and Part B. Part A enrolled and dosed 15 participants. Part B enrolled 55 participants, of whom 54 received at least one dose of study drug. Three participants who completed Part A subsequently continued into Part B and are therefore included in both study parts. As a result, the total number of unique participants enrolled across Parts A and B was 67.

Part A (15 Days)
Participant flow — Part A (15 Days)
MilestonePart A: ELX/TEZ/IVAPart B: ELX/TEZ/IVA
Started150
Safety set150
Completed150
Not completed00
Part B (24 Weeks)
Participant flow — Part B (24 Weeks)
MilestonePart A: ELX/TEZ/IVAPart B: ELX/TEZ/IVA
Started055
Safety set054
Completed053
Not completed02
Withdrew: Prematurely discontinued study01
Withdrew: Never dosed01

Outcome measures

PrimaryPart A: Observed Pre-dose Concentration (Ctrough) of ELX, TEZ, IVA, and Their Relevant Metabolites (M23-ELX, M1-TEX, M1-IVA)
Time frame:
At Day 15
Reported as:
Median · microgram per milliliter (μg/mL)
Part A: Observed Pre-dose Concentration (Ctrough) of ELX, TEZ, IVA, and Their Relevant Metabolites (M23-ELX, M1-TEX, M1-IVA)
microgram per milliliter (μg/mL)Part A: ELX/TEZ/IVA
ELX0.907 ± 0.447
TEZ0.691 ± 0.245
IVA0.151 ± 0.0669
M23-ELX0.474 ± 0.159
M1-TEZ4.56 ± 1.46
M1-IVA0.458 ± 0.178
PrimaryPart A: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame:
Day 1 up to Day 43
Reported as:
Count of participants · Participants
Part A: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsPart A: ELX/TEZ/IVA
Participants with TEAEs14
Participants with SAEs0
PrimaryPart B : Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame:
Day 1 up to Week 28
Reported as:
Count of participants · Participants
Part B : Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsPart B: ELX/TEZ/IVA
Participants with TEAEs53
Participants with SAEs6
SecondaryPart B: Observed Pre-dose Concentration (Ctrough) of ELX, TEZ, IVA, and Their Relevant Metabolites (M23-ELX, M1-TEZ, M1-IVA)
Time frame:
Day 15, Week 4, 12 and 16
Reported as:
Mean · microgram per milliliter (μg/mL)
Part B: Observed Pre-dose Concentration (Ctrough) of ELX, TEZ, IVA, and Their Relevant Metabolites (M23-ELX, M1-TEZ, M1-IVA)
microgram per milliliter (μg/mL)Part B: ELX/TEZ/IVA
Dosage1: ELX(Day 15)2.74 ± 1.87
Dosage1: ELX(Week 4)2.36 ± 1.10
Dosage1: ELX(Week 12)2.27 ± 1.47
Dosage1: ELX(Week 16)2.45 ± 1.34
Dosage1: TEZ (Day 15)1.74 ± 0.894
Dosage1: TEZ(Week 4)1.75 ± 1.02
Dosage1:TEZ(Week 12)1.71 ± 1.13
Dosage1: TEZ (Week 16)1.61 ± 0.729
Dosage1: IVA(Day 15)0.400 ± 0.244
Dosage1: IVA (Week 4)0.432 ± 0.317
Dosage1: IVA(Week 12)0.407 ± 0.376
Dosage1: IVA (Week 16)0.451 ± 0.298
Dosage1: M23-ELX(Day 15)2.03 ± 1.37
Dosage1: M23-ELX(Week 4)1.74 ± 0.896
Dosage1: M23-ELX(Week 12)1.77 ± 1.15
Dosage1: M23-ELX(Week 16)1.82 ± 1.02
Dosage1: M1-TEZ(Day 15)7.28 ± 2.22
Dosage1: M1-TEZ(Week 4)7.68 ± 2.56
Dosage1: M1-TEZ(Week 12)7.62 ± 2.08
Dosage1: M1-TEZ(Week 16)7.44 ± 1.91
Dosage1: M1-IVA(Day 15)1.07 ± 0.564
Dosage1: M1-IVA (Week 4)1.18 ± 0.596
Dosage1: M1-IVA(Week 12)1.25 ± 0.817
Dosage1: M1-IVA(Week 16)1.28 ± 0.694
Dosage2: ELX (Day 15)1.92 ± 1.42
Dosage2: ELX (Week 4)2.49 ± 1.83
Dosage2: ELX (Week 12)3.05 ± 2.30
Dosage2: ELX (Week 16)2.45 ± 1.00
Dosage2: TEZ (Day 15)1.57 ± 1.20
Dosage2: TEZ (Week 4)1.54 ± 0.725
Dosage2: TEZ (Week 12)1.54 ± 0.858
Dosage2: TEZ (Week 16)1.52 ± 0.547
Dosage2: IVA (Day 15)0.435 ± 0.434
Dosage2: IVA (Week 4)0.468 ± 0.489
Dosage2: IVA (Week 12)0.571 ± 0.695
Dosage2: IVA (Week 16)0.547 ± 0.358
Dosage2: M23-ELX (Day 15)1.26 ± 0.854
Dosage2: M23-ELX (Week 4)1.89 ± 1.35
Dosage2: M23-ELX (Week 12)2.16 ± 1.75
Dosage2: M23-ELX (Week 16)1.66 ± 0.819
Dosage2: M1-TEZ (Day 15)6.81 ± 2.53
Dosage2: M1-TEZ (Week 4)7.75 ± 2.09
Dosage2: M1-TEZ (Week 12)6.66 ± 2.35
Dosage2: M1-TEZ (Week 16)7.58 ± 1.38
Dosage2: M1-IVA (Day 15)1.09 ± 0.956
Dosage2: M1-IVA (Week 4)1.37 ± 1.33
Dosage2: M1-IVA (Week 12)1.36 ± 0.970
Dosage2: M1-IVA (Week 16)1.64 ± 1.04
SecondaryPart B: Absolute Change in Sweat Chloride (SwCl) From Baseline Through Week 24
Time frame:
From Baseline through Week 24
Reported as:
Least squares mean · Millimole per liter (mmol/L)
Part B: Absolute Change in Sweat Chloride (SwCl) From Baseline Through Week 24
Millimole per liter (mmol/L)Part B: ELX/TEZ/IVA
Part B: Absolute Change in Sweat Chloride (SwCl) From Baseline Through Week 24-71.8 (-75.4 to -68.2)

Adverse events

Collected over From Day 1 Through Safety Follow-up Period (up to Day 43 for Part A and up to Week 28 for Part B). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: ELX/TEZ/IVA0/15 (0%)0/15 (0%)14/15 (93.3%)
Part B: ELX/TEZ/IVA0/54 (0%)6/54 (11.1%)53/54 (98.1%)
Most frequent serious events
Most frequent serious events
EventPart A: ELX/TEZ/IVAPart B: ELX/TEZ/IVA
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations0/154/54
Respiratory syncytial virus infectionInfections and infestations0/151/54
Viral upper respiratory tract infectionInfections and infestations0/151/54
Pseudomonas test positiveInvestigations0/151/54
Most frequent other events
Showing 10 of 39
Most frequent other events
EventPart A: ELX/TEZ/IVAPart B: ELX/TEZ/IVA
CoughRespiratory, thoracic and mediastinal disorders3/1528/54
PyrexiaGeneral disorders1/1521/54
Upper respiratory tract infectionInfections and infestations5/1515/54
RhinorrhoeaRespiratory, thoracic and mediastinal disorders2/1515/54
ConstipationGastrointestinal disorders4/157/54
DiarrhoeaGastrointestinal disorders4/158/54
NasopharyngitisInfections and infestations0/1514/54
VomitingGastrointestinal disorders1/1513/54
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations0/1512/54
RhinitisInfections and infestations2/1512/54

Baseline characteristics

All participants who are enrolled (defined as participants having data in the clinical database) and carry the intended CFTR allele mutation and received at least 1 dose of study drug were included in the baseline analysis.

Age, Categorical
Age, Categorical(Participants)ELX/TEZ/IVA
Part A (15 Days) — <=18 years15
Part A (15 Days) — Between 18 and 65 years0
Part A (15 Days) — >=65 years0
Part B (24 Weeks) — <=18 years54
Part B (24 Weeks) — Between 18 and 65 years0
Part B (24 Weeks) — >=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)ELX/TEZ/IVA
Part A (15 Days) — Female4
Part A (15 Days) — Male11
Part B (24 Weeks) — Female22
Part B (24 Weeks) — Male32
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ELX/TEZ/IVA
Part A (15 Days) — Hispanic or Latino0
Part A (15 Days) — Not Hispanic or Latino15
Part A (15 Days) — Not Collected per Local Regulations0
Part B (24 Weeks) — Hispanic or Latino1
Part B (24 Weeks) — Not Hispanic or Latino50
Part B (24 Weeks) — Not Collected per Local Regulations3
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ELX/TEZ/IVA
Part A (15 Days) — White14
Part A (15 Days) — Asian0
Part A (15 Days) — Other1
Part A (15 Days) — Not collected per local regulations0
Part B (24 Weeks) — White51
Part B (24 Weeks) — Asian2
Part B (24 Weeks) — Other1
Part B (24 Weeks) — Not collected per local regulations0
08

Study locations

19 sites
  • Telethon Kids Institute
    Nedlands, Australia
  • The Royal Children's Hospital
    Parkville, Australia
  • Queensland Children's Hospital
    South Brisbane, Australia
  • The Children's Hospital at Westmead
    Westmead, Australia
  • The Hospital for Sick Children
    Toronto, Canada
  • British Columbia Children's Hospital
    Vancouver, Canada
  • Juliane Marie Center, Rigshospitalet
    Copenhagen, Denmark
  • Charite Paediatric Pulmonology Department
    Berlin, Germany
  • Kinderklinik III, Abt. fur Pneumologie
    Essen, Germany
  • Medizinische Hochschule Hannover
    Hanover, Germany
  • Erasmus Medical Center / Sophia Children's Hospital
    Rotterdam, Netherlands
  • Inselspital - Universitaetsspital Bern
    Bern, Switzerland
  • Kinderspital Zuerich
    Zurich, Switzerland
  • Children and Young Adults Research Unit
    Cardiff, United Kingdom
  • Leeds General Infirmary
    Leeds, United Kingdom
  • Alder Hey Children's NHS Foundation Trust
    Liverpool, United Kingdom
  • Great Ormond Street Hospital for Children
    London, United Kingdom
  • Royal Brompton Hospital
    London, United Kingdom
  • Southampton General Hospital
    Southampton, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in Sep 2025, 26 months.

Results were first posted in Oct 2026, 1 year 1 month after primary completion.

Of 58 industry-sponsored phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 26 months is close to that.

Counting every sponsor, half of 67 studies reached it within 26 months; a quarter within 16 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2023
First posted
May 31, 2023
StartActual
Jun 27, 2023
Primary completionActual
Sep 4, 2025
CompletionActual
Sep 4, 2025
Results first posted
Oct 15, 2026
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 15, 2026
Enrollment
70→67
Oct 15, 2026
Interventions
Arms added: Part A: ELX/TEZ/IVA·Part B: ELX/TEZ/IVA; arms removed: Part A·Part B
Oct 15, 2026
Primary outcomes
3 edited
What changed in the outcomes
  • EditedPart A: Observed Pre-dose Concentration (Ctrough) of ELX, TEZ, IVA, and theirTheir Relevant Metabolites (M23-ELX, M1-TEX, M1-IVA)Time frame: Day 1 up to Day 15 → At Day 15
  • EditedPart A: Safety and Tolerability as Assessed by Number of Participants withWith Treatment-Emergent Adverse Events (AEsTEAEs) and Serious Adverse Events (SAEs)Time frame: Day 1 up to Day 43
  • EditedPart B : Safety and Tolerability as Assessed by Number of Participants withWith Treatment-Emergent Adverse Events (AEsTEAEs) and Serious Adverse Events (SAEs)Time frame: Day 1 up to Week 28
Oct 15, 2026
Documents
Secondary outcomes
2 edited
What changed in the outcomes
  • EditedPart B: Observed Pre-dose Concentration (Ctrough) of ELX, TEZ, IVA, and theirTheir Relevant Metabolites (M23-ELX, M1-TEZ, M1-IVA)Time frame: Day 15 up to Week 16 → Day 15, Week 4, 12 and 16
  • EditedPart B: Absolute Change in Sweat Chloride (SwCl) From Baseline Through Week 24Time frame: From Baseline Through Week 24 → From Baseline through Week 24
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Results posted
    Enrollment 70→67
    Primary outcomes 3 edited
    What changed in the outcomes
    • EditedPart A: Observed Pre-dose Concentration (Ctrough) of ELX, TEZ, IVA, and theirTheir Relevant Metabolites (M23-ELX, M1-TEX, M1-IVA)Time frame: Day 1 up to Day 15 → At Day 15
    • EditedPart A: Safety and Tolerability as Assessed by Number of Participants withWith Treatment-Emergent Adverse Events (AEsTEAEs) and Serious Adverse Events (SAEs)Time frame: Day 1 up to Day 43
    • EditedPart B : Safety and Tolerability as Assessed by Number of Participants withWith Treatment-Emergent Adverse Events (AEsTEAEs) and Serious Adverse Events (SAEs)Time frame: Day 1 up to Week 28
    Secondary outcomes 2 edited
    What changed in the outcomes
    • EditedPart B: Observed Pre-dose Concentration (Ctrough) of ELX, TEZ, IVA, and theirTheir Relevant Metabolites (M23-ELX, M1-TEZ, M1-IVA)Time frame: Day 15 up to Week 16 → Day 15, Week 4, 12 and 16
    • EditedPart B: Absolute Change in Sweat Chloride (SwCl) From Baseline Through Week 24Time frame: From Baseline Through Week 24 → From Baseline through Week 24
    Interventions Arms added: Part A: ELX/TEZ/IVA·Part B: ELX/TEZ/IVA; arms removed: Part A·Part B
    + 4 other changes: identifiers, verification date, description and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05882357
Responsible party
Sponsor
First posted
May 31, 2023
Start date
Jun 27, 2023
Primary completion
Sep 4, 2025
Completion
Sep 4, 2025
Results posted
Oct 15, 2026
Last update
Oct 15, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Elexacaftor · Tezacaftor · Ivacaftor

Start the discussion